VERTELLUS PC phosphorylcholine coating, implantable medical hydrophilic super-slip coating, polymer biomimetic coating, inhibits protein accumulation, reduces blood activation

Introduction to PC Technology
PC is the abbreviation of phosphorylcholine, which exists in various phospholipids, especially in The chemical name for the polar headgroups in phospholipids that make up the bilayer structure of cell membranes.
PC technology is a proprietary technology platform of methacrylic acid polymers containing phosphorylcholine. These biomimetic materials are built on the body's own chemistry, yet they are entirely synthetic, allowing precise control over purity, molecular structure, and avoiding the risks associated with animal-derived ingredients. They can provide a simple and effective solution to the biosensitivity challenges faced by medical devices and can be tailored to specific application needs.

Product List
Ventruus Biomaterials offers a wide range of polymer coatings and monoliths to utilize PC Various features and benefits that can be provided:

Polymer

Brief description

Apply

PC1036

Standard CrosslinkedPCcoating, highly durable drug delivery matrix

BiodivYsio ® Dexamet® TriMaxx™, Endeavor®Brackets

PC1059

Standard Non-crosslinkedPCcoatings are stabilized by hydrophobic surface interactions

leader Silk,CPBsystem

PC2118

cross UnitedPC<span style="font-fam�� and surfactant properties have potential benefits in non-medical areas.
Some examples of applicable properties, benefits and potential applications are summarized below:

Performance	Advantages	Potential fields of application
Reduce Protein Attachment	Reduce Fouling; easier to clean	Food and beverage processing equipment; pharmaceutical processing equipment
Reduce Protein Attachment	Reduce Use of Strong Cleaning Chemicals	None Toxic Marine Antifouling
Reduce Bacterial Adhesion and Biofilm Formation	Ibid , while reducing infection/pollution/Risk of spoilage	Use Keep it Clean in Hospital/Easy Clean Surface; Water Filtration System; Latex
Dear Water and moisturizing	Strengthen Hydrating and Conditioning	Cosmetics ;Functional/Reactive Textiles
Transfer Active Substance	active Substance and the above advantages	Cosmetics ;Health care products

Application of PC Technology™ in Drug Delivery
In recent years, the development of drug-device combination products has Significant changes. Perhaps the clearest example has always been the drug-eluting stent (DES) market, which has exploded from $1.5 billion to $5 billion in two years. PC coating has played an important role in this field. Abbott's PC dimethasone stent, Dexamet®, the second DES to market in Europe, and Medtronic's PC-coated otarolimus-eluting Endeavor® DES system, were notable in a two-year follow-up of 1,300 patients In the trial, there was no late frame thrombosis. These application examples highlight the value of PC materials to the medical device market.
The flexible chemical properties of PC polymers make it possible to modify various monomers, so that the polymers can be customized according to different active substances and the drug elution performance can be fine-tuned. Breakthrough drug-device combinations that demonstrate clinical benefits through controlled drug release, and Ventruus' expertise is well suited to serve the development and commercialization of combination products.

PC coating can:
o Adsorption of high molecular weight compounds
o Absorption of low molecular weight drugs
o Exhibit precise dosing and controlled release
o Once released, remain stable

PC coating can deliver:
o Anti-inflammatory drugs o Pain relievers
o Antimicrobials o Hormones
o DNA fragments used in gene therapy

Activities that have been studied Specific examples of substances:
o Dexamethasone o Estradiol
o Paclitaxel o Sirolimus
o Batimastat o Angiopep
o Dipyridamole

Manufacturer Information
Headquarters and The application laboratory is based in Hampshire, UK. The division is part of Van Truust Specialty Products UK Limited in the North of England and the company's operations are accredited to an ISO9001:2008 Quality Management System (Certificate No. FM02222). Van Truus Specialty Products UK Ltd has facilities to produce multi-tonne PC materials and has recently opened a new polymer chemistry R&D laboratory to support the Biomaterials Division's operations. Ventrux is ideally suited to assist medical supply companies in applying the benefits of PC technology to address unmet clinical needs and provide value-added, differentiated products.

Perhaps the clearest example has always been the drug-eluting stent (DES) market, which has exploded from $1.5 billion to $5 billion in two years. PC coating has played an important role in this field. Abbott's PC dimethasone stent, Dexamet®, the second DES to market in Europe, and Medtronic's PC-coated otarolimus-eluting Endeavor® DES system, were notable in a two-year follow-up of 1,300 patients In the trial, there was no late frame thrombosis. These application examples highlight the value of PC materials to the medical device market.
The flexible chemical properties of PC polymers make it possible to modify various monomers, so that the polymers can be customized according to different active substances and the drug elution performance can be fine-tuned. Breakthrough drug-device combinations that demonstrate clinical benefits through controlled drug release, and Ventruus' expertise is well suited to serve the development and commercialization of combination products.

PC coating can:
o Adsorption of high molecular weight compounds
o Absorption of low molecular weight drugs
o Exhibit precise dosing and controlled release
o Once released, remain stable

PC coating can deliver:
o Anti-inflammatory drugs o Pain relievers
o Antimicrobials o Hormones
o DNA fragments used in gene therapy

Activities that have been studied Specific examples of substances:
o Dexamethasone o Estradiol
o Paclitaxel o Sirolimus
o Batimastat o Angiopep
o Dipyridamole

This article is from the Internet, does not represent the position of Toluene diisocyanate reproduced please specify the source.https://www.allhdi.com/archives/1113